Israel-based innovative therapies developer Therapix Biosciences Ltd. revealed that its venture fund, ALIVE HealthTech Fund, is planning to secure $50 million in commitments by the end of the quarter and $150 million by the end of 2019.
The new vehicle is a joint venture of Therapix Biosciences, Israeli health maintenance company Maccabi Healthcare Services, medical centers chain Assuta Medical Centre Ltd. and Australian equities fund manager CBG Asset Management.
The founding partners have invested $32 million in the vehicle. Maccabi Healthcare and Assuta Medical will provide ALIVE HealthTech with access to clinical trials, medical databases, and commercial pilots.
Therapix and CBG Asset will co-manage ALIVE HealthTech Fund, which plans to commit primarily in late-stage startups in the sectors of medical devices and software, digital health, personalized healthcare and nutrition-related technologies.